GSE258991 enzalutamide DK1 [Tursiops] 5 v 4 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE258991_enzalutamide_DK1 [Tursiops]_5_v_4_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE258991_enzalutamide_DK1 [Tursiops]_5_v_4_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE258991_enzalutamide_DK1 [Tursiops]_5_v_4_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE258991_enzalutamide_DK1 [Tursiops]_5_v_4_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

H4 clustered histone 15

Gene

H2B clustered histone 8

Gene

BAIAP2 divergent transcript

Gene

H2A clustered histone 4

Gene

taxilin gamma Y-linked (pseudogene)

Gene

CDH13 antisense RNA 2

Gene

long intergenic non-protein coding RNA 3124

Gene

H4 clustered histone 14

Gene

H2B clustered histone 6

Gene

RNA component of signal recognition particle 7SL2

  • Gene

    H4 clustered histone 15


  • Gene

    H2B clustered histone 8


  • Gene

    BAIAP2 divergent transcript


  • Gene

    H2A clustered histone 4


  • Gene

    taxilin gamma Y-linked (pseudogene)


  • Gene

    CDH13 antisense RNA 2


  • Gene

    long intergenic non-protein coding RNA 3124


  • Gene

    H4 clustered histone 14


  • Gene

    H2B clustered histone 6


  • Gene

    RNA component of signal recognition particle 7SL2

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.